Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cholangiocarcinoma 4Biliary Tract Neoplasms 3Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Klatskin Tumor 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 65Rituximab 62fludarabine 40Etoposide 25Lenalidomide 19fludarabine phosphate 17Immunotherapy, Adoptive 17Doxorubicin 17Cytarabine 17Vincristine 15Magnetic Resonance Spectroscopy 14Prednisone 13pembrolizumab 11Specimen Handling 11Dexamethasone 10CT-P10 10Melphalan 9Carmustine 9Carboplatin 9Bortezomib 9Bendamustine Hydrochloride 9obinutuzumab 8ibrutinib 8Mycophenolic Acid 8Biopsy 8Radiotherapy 7Ifosfamide 7polatuzumab vedotin 6Whole-Body Irradiation 6Methotrexate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell × gemcitabine-oxaliplatin regimen × Clear all
NCT00169195 2015-09-02

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Lymphoma Study Association

Phase 2 Completed
49 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡